No Data
No Data
Nikkei Stock Average Contribution Ranking (Closing) - The Nikkei Stock Average has fallen significantly for 7 consecutive days, with First Retail and Advantest pushing down by about 108 yen in 2 stocks.
At the closing of the market on the 11th, the number of rising stocks in the Nikkei average composition was 12, the number of falling stocks was 211, and the number of unchanged stocks was 2. The U.S. market on the 10th was mixed. The Dow average closed at 40,736.96, down 92.63 points (−0.23%), the Nasdaq closed at 17,025.88, up 141.28 points (+0.84%), and the S&P500 closed at 5,495.52, up 24.47 points (+0.45%). Expectations of a soft landing continued to drive buying, with opening.
NEDO's "Next-Generation Technology Development Project for Floating Offshore Wind Power Generation" has been adopted - Verification of the feasibility of large-scale floating vertical axis wind turbines.
On September 11, 2024, Tweet Corporation Albatross Technology (hereinafter referred to as Albatross), Electric Power Development Corporation (hereinafter referred to as J-Power), Tokyo Electric Power Holdings Corporation (hereinafter referred to as TEPCO HD), Kawasaki Kisen Kaisha Ltd. (hereinafter referred to as Kawasaki Kisen Kaisha), and Sumitomo Heavy Industries Marine & Engineering Co., Ltd. (hereinafter referred to as SHI-ME), a subsidiary of Sumitomo Heavy Industries, jointly announced with the National Institute of Advanced Industrial Science and Technology, the National Institute of Natural Sciences, and the National Institute for Materials Science that they have established a consortium called the New Energy and Industrial Technology Development Organization.
List of conversion stocks (Part 3) [List of parabolic signal conversion stocks]
○ Sell conversion stock list market Code Stock Name Close SAR Tokyo Main Board <4538> Fusso Pharmaceutical 2188 2298<4543> Terumo 2645 2810<4559> Zeria Pharmaceutical 2251 2324<4633> Sakata Inx 1577 1704<4674> Cresco
Stella Pharma has entered the rankings, signing clinical trial contracts for boron neutron capture therapy with the National Cancer Center, etc.
Stella Pharma <4888> has entered the rankings as of 9:32 am. It is significantly higher. After the end of trading the previous day, it was announced that Stella Pharma has signed contracts with the National Cancer Center, Sumitomo Heavy <6302>, and CICS for the phase 1/2 basket trial of boron neutron capture therapy (NCT) for patients with inoperable and unresectable recurrent thoracic solid malignant tumors, which seems to have become a trigger for buying. The purpose is to evaluate the safety and efficacy of BNCT using boron agents.
Rakuauria Pharmaceuticals, Renascience, and others
<2586> Flettner 15th round of subscription rights (with exercise price adjustment clause) large-scale exercise 2-day delivery of shares, 3.37 million shares <2934> J Frontier Securities Report on extension of submission deadline for approval application for approval <4572> Karnabio BTK inhibitor AS-1763 Phase 1b trial Dose expansion part commencement decided <4579> Rakuria Drug development gastric acid secretion inhibitor tegoprazan Colombia marketing approval obtained <4888> Stellar Pharma
We will be exhibiting at the 17th International Secondary Battery Exhibition (Autumn).
Sumitomo Heavy Industries, Ltd. Mechatronics Division will exhibit at the 17th International Secondary Battery Exhibition Autumn, which will be held from October 2nd (Wednesday) to October 4th (Friday) 2024 at Makuhari Messe. Booth location: E17-5. Please register for a visitor badge on the official website. Highlights of our exhibition: We will introduce our unique control technology that plays an active role in the rapidly growing secondary battery production equipment market.
No Data
No Data